Skip to main content
Premium Trial:

Request an Annual Quote

Bruker s Revenues Soar 11 Percent, Loss Turns into Profit in Q2 of 2005

NEW YORK, Aug. 3 (GenomeWeb News) - Bruker BioSciences today reported increased revenues and a small net profit for the second quarter of 2005.


Revenues totaled $71.4 million for the quarter, up 11 percent over last year's $64.1 million during the same period. Of this, $37.4 million came from Bruker Daltonics, Bruker's mass spec business, up 7 percent from $34.9 million during the last year's second quarter. About 70 percent of the Daltonics revenues stem from mass spec systems for life sciences.


The company's research and development costs increased slightly, to $11 million, from $10.3 million during the second quarter of 2004.


Bruker reported a net income of $284,000, or $0 per share, up from a net loss of $4.4 million, or $.05 per share, for the same period last year.


As of June 30, Bruker had $92 million in cash and short-term investments.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.